MYAMBUTOL (ethambutol hydrochloride) by Bayer is clinical pharmacology ethambutol hcl, following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/ml in serum 2 to 4 hours after administration. Approved for pulmonary tuberculosis. First approved in 1967.
Drug data last refreshed 17h ago
Myambutol (ethambutol hydrochloride) is an oral small-molecule antimycobacterial agent approved in 1967 for treatment of tuberculosis, Mycobacterium avium-intracellulare infection, and HIV-related opportunistic infections. It works by inhibiting mycobacterial cell metabolism and arresting multiplication through interference with metabolite synthesis. The drug is typically used in combination therapy to reduce resistance emergence.
As a legacy product approaching loss of exclusivity with minimal Part D spending ($10K in 2023), the commercial team is likely small and focused on maintaining market position in a contracted indication portfolio.
CLINICAL PHARMACOLOGY ETHAMBUTOL HCL, following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/mL in serum 2 to 4 hours after administration. When the drug is administered daily for longer periods of time at this dose, serum levels are similar. The serum level of…
Worked on MYAMBUTOL at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Myambutol offers limited career growth potential given its LOE-approaching lifecycle and minimal new business development activity. Professionals joining this portfolio should expect focus on margin preservation, generic competition management, and consolidation of sales infrastructure rather than market expansion or innovation initiatives.